Abstract
MDM2 and MDMX are oncoproteins that negatively regulate the activity and stability of the tumor suppressor protein p53. The inhibitors of protein-protein interactions (PPIs) of MDM2-p53 and MDMX-p53 represent potential anticancer agents. In this study, a novel approach for identifying MDM2-p53 and MDMX-p53 PPI inhibitor candidates by affinity-based screening using a chemical array has been established. A number of compounds from an in-house compound library, which were immobilized onto a chemical array, were screened for interaction with fluorescence-labeled MDM2 and MDMX proteins. The subsequent fluorescent polarization assay identified several compounds that inhibited MDM2-p53 and MDMX-p53 interactions.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Cell Cycle Proteins
-
Dose-Response Relationship, Drug
-
High-Throughput Screening Assays*
-
Humans
-
Models, Molecular
-
Molecular Structure
-
Nuclear Proteins / antagonists & inhibitors*
-
Nuclear Proteins / metabolism
-
Protein Binding / drug effects
-
Proto-Oncogene Proteins / antagonists & inhibitors*
-
Proto-Oncogene Proteins / metabolism
-
Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors*
-
Proto-Oncogene Proteins c-mdm2 / metabolism
-
Structure-Activity Relationship
-
Tumor Suppressor Protein p53 / antagonists & inhibitors*
-
Tumor Suppressor Protein p53 / metabolism
Substances
-
Cell Cycle Proteins
-
MDM4 protein, human
-
Nuclear Proteins
-
Proto-Oncogene Proteins
-
Tumor Suppressor Protein p53
-
MDM2 protein, human
-
Proto-Oncogene Proteins c-mdm2